V
Vaishali Sanchorawala
Researcher at Boston University
Publications - 281
Citations - 9703
Vaishali Sanchorawala is an academic researcher from Boston University. The author has contributed to research in topics: AL amyloidosis & Amyloidosis. The author has an hindex of 42, co-authored 244 publications receiving 7910 citations. Previous affiliations of Vaishali Sanchorawala include Yıldırım Beyazıt University & Harvard University.
Papers
More filters
Journal ArticleDOI
Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis
Morie A. Gertz,Raymond L. Comenzo,Rodney H. Falk,Jean Paul Fermand,Bouke P. C. Hazenberg,Philip N. Hawkins,Giampaolo Merlini,Philippe Moreau,Pierre Ronco,Vaishali Sanchorawala,Orhan Sezer,Alan Solomon,Giles Grateau +12 more
TL;DR: A consensus panel was convened comprising 13 specialists actively involved in the treatment of patients with amyloidosis, and a consensus was developed defining each organ involved and the criteria for response.
Journal ArticleDOI
High-Dose Melphalan and Autologous Stem-Cell Transplantation in Patients with AL Amyloidosis: An 8-Year Study
Martha Skinner,Vaishali Sanchorawala,David C. Seldin,Laura M. Dember,Rodney H. Falk,John L. Berk,Jennifer J. Anderson,Carl O'Hara,Kathleen T. Finn,Caryn A. Libbey,Janice F. Wiesman,Karen Quillen,Niall Swan,Daniel G. Wright +13 more
TL;DR: Analysis of consecutive patients with AL amyloidosis from 6 separate trials over 8 years shows that high-dose intravenous melphalan therapy combined with autologous stem-cell transplantation greatly improves duration of survival and ameliorates organ dysfunction.
Journal ArticleDOI
Systemic immunoglobulin light chain amyloidosis.
Giampaolo Merlini,Angela Dispenzieri,Vaishali Sanchorawala,Stefan Schönland,Giovanni Palladini,Philip N. Hawkins,Morie A. Gertz +6 more
TL;DR: Passive immunotherapies targeting clonal plasma cells and directly accelerating removal of amyloid deposits promise to further improve the overall outlook of this increasingly treatable disease.
Journal ArticleDOI
Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis : Survival and responses in 25 patients
Raymond L. Comenzo,Evan Vosburgh,Rodney H. Falk,Vaishali Sanchorawala,Johann Reisinger,Simon W Dubrey,Laura M. Dember,John L. Berk,Gorgun Akpek,Michael P. LaValley,Carl O'Hara,Charles F. Arkin,Daniel G. Wright,Martha Skinner +13 more
TL;DR: Dose-intensive therapy should currently be considered as the preferred therapy for patients with AL amyloidosis who meet functional criteria for autologous transplantation, and the improvement in the median performance status of the 17 survivors at follow-up is statistically significant versus baseline.
Journal ArticleDOI
Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis
Raymond L. Comenzo,Donna E. Reece,Giovanni Palladini,David C. Seldin,Vaishali Sanchorawala,Heather Landau,Rodney H. Falk,Karen Wells,Alan Solomon,Ashutosh D. Wechalekar,Jeffrey A. Zonder,Angela Dispenzieri,Morie A. Gertz,Howard Streicher,Martha Skinner,Robert A. Kyle,Giampaolo Merlini +16 more
TL;DR: This manuscript provides a framework for the design and conduct of systematic collaborative clinical research in AL to encourage more rapid testing of therapies and to expedite new drug development and approval.